Skip to main
IGMS
IGMS logo

IGMS Stock Forecast & Price Target

IGMS Analyst Ratings

Based on 14 analyst ratings
Hold
Strong Buy 14%
Buy 21%
Hold 57%
Sell 7%
Strong Sell 0%

Bulls say

IGM Biosciences Inc. is positioned favorably due to its novel IgM antibody technology platform, which has shown promise in developing therapeutics for several serious medical conditions, including cancer and autoimmune diseases. The ongoing collaboration with Sanofi (SNY) to develop IgM agonists presents significant revenue potential, with nearly $3 billion in possible milestone earnings pending the successful development of viable candidates. Additionally, the differentiated safety profiles of IgM-based therapeutics may enhance their competitive edge in the expanding autoimmune treatment market, further supporting a positive outlook for the company's stock.

Bears say

IGM Biosciences Inc. faces a negative outlook primarily due to the discontinuation of its key IgM-based bispecific antibody programs, which undermines potential revenue streams and raises concerns about the company's long-term viability. Additionally, the firm's inability to secure external funding, coupled with disappointing efficacy results from current clinical candidates such as Aplitabart and Imvotamab, further exacerbates financial instability. As operational costs continue to rise amid non-revenue-generating status, the likelihood of significant fluctuations in stock price remains high, indicating a precarious position for shareholders.

IGMS has been analyzed by 14 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 21% recommend Buy, 57% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of IGM Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About IGM Biosciences Inc (IGMS) Forecast

Analysts have given IGMS a Hold based on their latest research and market trends.

According to 14 analysts, IGMS has a Hold consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

IGM Biosciences Inc (IGMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.